[Abstract] To describe temporal trend and characteristics of newly HIV-diagnosed patients in a medical care area in Northwest Spain over the last 10 years. All newly diagnosed patients for HIV-infection from 2004 to 2013 at a reference medical care area in Northwest of Spain were identified. Epidemiological, virological, immunological, and clinical data, as well as HIV genotype and drug resistance information were recorded. A total of 565 newly HIV-diagnosed patients were identified. The number of new cases increased in the last 5 years (66 cases/year). Overall, 53.1% had a median CD4 counts < 350 cells/µl and 33.6% had an AIDS defining criteria. Non-B variants were found in 34.4% of patients being subtype F (25.8%) the most common non-B su...
<p>Asterisks indicate that the frequency of TDR to NRTIs from 10% in 2004 to 2% in 2012 was statisti...
Background Molecular surveillance of newly diagnosed HIV-infections is important for tracking trend...
Introduction: Late HIV diagnosis is common and associated with an increased risk of clinical progres...
OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non-...
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with ...
OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non...
Producción CientíficaThe prevalence of drug resistance mutations was 12.1% among 198 persons who exp...
Background: Early diagnosis of HIV infection can prevent morbidity and mortality as well as reduce H...
[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) ini...
Most of the non-B HIV-1 subtypes are predominant in Sub-Saharan Africa and India although they have ...
[Abstract] Background. HIV-1 subtype B is the predominant one in European regions several, while oth...
AbstractObjectiveTo present surveillance data on advanced disease (AD) and late presentation (LP) of...
With the purpose of reducing the well-known negative impact of late presentation (LP) on people livi...
The prevalence of transmitted HIV drug resistance (TDR) is stabilizing or decreasing in developed co...
During 2000 to 2009, data on people undergoing HIV testing and on those newly diagnosed with HIV wer...
<p>Asterisks indicate that the frequency of TDR to NRTIs from 10% in 2004 to 2% in 2012 was statisti...
Background Molecular surveillance of newly diagnosed HIV-infections is important for tracking trend...
Introduction: Late HIV diagnosis is common and associated with an increased risk of clinical progres...
OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non-...
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with ...
OBJECTIVES: To evaluate the prevalence of transmitted drug resistance (TDR) and non...
Producción CientíficaThe prevalence of drug resistance mutations was 12.1% among 198 persons who exp...
Background: Early diagnosis of HIV infection can prevent morbidity and mortality as well as reduce H...
[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) ini...
Most of the non-B HIV-1 subtypes are predominant in Sub-Saharan Africa and India although they have ...
[Abstract] Background. HIV-1 subtype B is the predominant one in European regions several, while oth...
AbstractObjectiveTo present surveillance data on advanced disease (AD) and late presentation (LP) of...
With the purpose of reducing the well-known negative impact of late presentation (LP) on people livi...
The prevalence of transmitted HIV drug resistance (TDR) is stabilizing or decreasing in developed co...
During 2000 to 2009, data on people undergoing HIV testing and on those newly diagnosed with HIV wer...
<p>Asterisks indicate that the frequency of TDR to NRTIs from 10% in 2004 to 2% in 2012 was statisti...
Background Molecular surveillance of newly diagnosed HIV-infections is important for tracking trend...
Introduction: Late HIV diagnosis is common and associated with an increased risk of clinical progres...